China Pharma Holdings, Inc.CPHINYSE
Loading
Year-over-year SG&A expense growth
Percentile
P54
Within normal range
vs 2Y Ago
-0.1x
Contraction
Streak
2 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q3 2025 | -7.24% |
| Q2 2025 | -8.78% |
| Q1 2025 | -42.52% |
| Q4 2024 | 115.56% |
| Q3 2024 | 135.91% |
| Q2 2024 | -65.92% |
| Q1 2024 | -37.15% |
| Q4 2023 | 109.66% |
| Q3 2023 | 60.65% |
| Q2 2023 | -49.89% |
| Q1 2023 | -52.89% |
| Q4 2022 | 122.74% |
| Q3 2022 | -0.65% |
| Q2 2022 | -22.23% |
| Q1 2022 | -39.53% |
| Q4 2021 | 162.96% |
| Q3 2021 | -43.73% |
| Q2 2021 | -1.54% |
| Q1 2021 | -40.74% |
| Q4 2020 | 40.64% |
| Q3 2020 | -10.04% |
| Q2 2020 | 46.94% |
| Q1 2020 | -63.30% |
| Q4 2019 | 105.64% |
| Q3 2019 | 12.68% |
| Q2 2019 | -7.39% |
| Q1 2019 | -45.79% |
| Q4 2018 | 33.61% |
| Q3 2018 | 17.16% |
| Q2 2018 | -8.77% |
| Q1 2018 | -38.14% |
| Q4 2017 | 82.95% |
| Q3 2017 | -26.82% |
| Q2 2017 | 24.77% |
| Q1 2017 | -47.36% |
| Q4 2016 | 76.40% |
| Q3 2016 | -25.45% |
| Q2 2016 | -12.31% |
| Q1 2016 | -67.90% |
| Q4 2015 | 259.01% |